As part of a bold expansion into the $60 billion global drug delivery market, Rainbow BioSciences, the biotech division of Rainbow Coral Corp. (RBCC), today announced it has formed a new partnership to solve the problems posed by systemic drug delivery.
RBCC signed a joint venture agreement with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before. The company has developed and patented these novel, tunable technologies with the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity.
Rainbow Coral Corp. (OTCBB: RBCC), a biotech company focused on delivering new medical technologies and innovations, today reports its anticipation of partnering with a cutting-edge genome-mapping facility in Houston in the next few weeks.
The genetic testing sector is one of the fastest-growing segments of the global biotech industry, with some market experts expecting it to reach $2.2 billion by 2017. The cutting-edge science of pharmacogenomics is a field of study resulting from the Human Genome Project that seeks to help doctors assess genetic variations in patients in order to create more effective, optimized drug treatment plans.